--- title: "Jade Biosciences (JBIO) news: offering and merger" url: "https://aibio.space/companies/jade-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "JBIO offering and merger news: Jade Biosciences agrees to $135 million private placement at $9.14 per share. Jade Biosciences, Inc." --- JBIO Jade Biosciences, Inc. NASDAQ · United States # Jade Biosciences (JBIO) news JBIO offering and merger news Financings · 2025-10-07 ## [Jade Biosciences agrees to $135 million private placement at $9.14 per share](https://aibio.space/news/jade-biosciences-agrees-135-million-private-placement-9-14-share/) Jade Biosciences agreed to a PIPE financing of about $135 million at $9.14 per share, with Jefferies, TD Cowen, Stifel and Wedbush named as placement agents, and says its cash will fund operations into the first half of 2028. ## Latest Jade Biosciences news 1. 2025-05-14 Mergers [Jade Biosciences files Q1 financials after Aerovate merger and $334.2 million financing](https://aibio.space/news/jade-biosciences-files-q1-financials-after-aerovate-merger-334-2/) Jade Biosciences (Nasdaq: JBIO) reported a net loss of $38,169 thousand and cash of $49,929 thousand for the quarter ended March 31, 2025, a period that ended before the merger and pre-closing financing closed April 28. 2. 2025-05-14 Mergers [Jade Biosciences (formerly Aerovate) details $334.2 million pre-merger financing](https://aibio.space/news/jade-biosciences-formerly-aerovate-details-334-2-million-pre-merger/) Aerovate Therapeutics took the Jade Biosciences name when the deal closed on April 28, 2025. Pre-merger Jade's management team runs the combined company. 3. 2025-05-01 Mergers [Aerovate Therapeutics (now Jade Biosciences) completes merger and private placement](https://aibio.space/news/aerovate-therapeutics-now-jade-biosciences-completes-merger-private/) Aerovate Therapeutics, whose only drug candidate missed its Phase 2b primary endpoint, closed its merger with Jade Biosciences on April 28, 2025. Aerovate holders kept about 1.4% of the combined company, and the financing includes $95 million of converted notes. 4. 2025-03-03 Mergers [Aerovate Therapeutics (now Jade Biosciences) files merger material from Jade](https://aibio.space/news/aerovate-therapeutics-now-jade-biosciences-files-merger-material-jade/) Aerovate filed a Jade communication on March 3, 2025, under their October 30, 2024 merger agreement. The combined company is expected to trade on Nasdaq as JBIO. ## Jade Biosciences at a glance - **Ticker**: JBIO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $461.2 million ### Related companies - [Sana Biotechnology](https://aibio.space/companies/sana-biotechnology/) NASDAQ: SANA - [AFFYMAX INC](https://aibio.space/companies/affymax/) OTC: AFFY - [PepGen](https://aibio.space/companies/pepgen/) NASDAQ: PEPG - [Eloxx Pharmaceuticals](https://aibio.space/companies/eloxx-pharmaceuticals/) NASDAQ: ELOX - [Humacyte](https://aibio.space/companies/humacyte/) NASDAQ: HUMA - [PaxMedica](https://aibio.space/companies/paxmedica/) OTC: PXMD - [Cadrenal Therapeutics](https://aibio.space/companies/cadrenal-therapeutics/) NASDAQ: CVKD - [Fractyl Health](https://aibio.space/companies/fractyl-health/) NASDAQ: GUTS ### Also on NASDAQ - [Fulgent Genetics](https://aibio.space/companies/fulgent-genetics/) FLGT - [HeartBeam](https://aibio.space/companies/heartbeam/) BEATW - [United Therapeutics](https://aibio.space/companies/united-therapeutics/) UTHR - [Vivani Medical](https://aibio.space/companies/vivani-medical/) VANI - [First Tracks Biotherapeutics](https://aibio.space/companies/first-tracks-biotherapeutics/) TRAX - [Processa Pharmaceuticals](https://aibio.space/companies/processa-pharmaceuticals/) PCSA ## What Jade Biosciences does Jade Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapies for patients with autoimmune diseases. Its approach is to develop biologics against emerging targets supported by third-party clinical data and to overcome shortcomings of existing candidates in potency, bioavailability, formulation and pharmacokinetic properties. Its lead candidate, JADE101, is a half-life extended monoclonal antibody targeting APRIL, which the company plans to develop initially for IgA nephropathy (IgAN). A Phase 1 trial of JADE101 in healthy volunteers in New Zealand began in August 2025, with interim data expected in the second quarter of 2026, and a Phase 2 trial in IgAN patients is planned for the middle of 2026. Its second candidate, JADE201, is a half-life extended, afucosylated monoclonal antibody targeting BAFF-R for multiple autoimmune disorders. A third candidate, JADE301, targets a pathway the company has not disclosed. | Product or program | What it is | Stage | |---|---|---| | JADE101 | Half-life extended antibody targeting APRIL for IgA nephropathy | Phase 1; Phase 2 planned | | JADE201 | Half-life extended, afucosylated antibody targeting BAFF-R for autoimmune disorders | | | JADE301 | Monoclonal antibody targeting an undisclosed pathway | | Summarised from the company's [10-K filed Mar 6, 2026](https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/ck0001798749-20251231.htm). ## Jade Biosciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$93.1 million](https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/) | [$53.2 million](https://www.sec.gov/Archives/edgar/data/1798749/000155837025003750/) | | Net income (loss) | [-$127.4 million](https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/) | [-$69.6 million](https://www.sec.gov/Archives/edgar/data/1798749/000155837025003750/) | | Cash from operations | [-$94.7 million](https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/) | [-$71.2 million](https://www.sec.gov/Archives/edgar/data/1798749/000155837025003750/) | | Cash and equivalents | [$88.4 million](https://www.sec.gov/Archives/edgar/data/1798749/000119312526341242/) | [$69.4 million](https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/) | | Short-term investments | [$247.7 million](https://www.sec.gov/Archives/edgar/data/1798749/000119312526341242/) | [$0](https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $107.2 million, plus short-term investments of $354.0 million, $461.2 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Jade Biosciences Has Jade Biosciences raised money recently? Our latest story on this, dated Oct 7, 2025: "Jade Biosciences agrees to $135 million private placement at $9.14 per share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jade-biosciences-agrees-135-million-private-placement-9-14-share/). Is Jade Biosciences involved in a merger or acquisition? Our latest story on this, dated May 14, 2025: "Jade Biosciences files Q1 financials after Aerovate merger and $334.2 million financing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jade-biosciences-files-q1-financials-after-aerovate-merger-334-2/). What is the ticker symbol of Jade Biosciences? Jade Biosciences, Inc. trades under the ticker JBIO on NASDAQ. Where is Jade Biosciences listed? Jade Biosciences, Inc. is listed on NASDAQ. What is the SEC CIK of Jade Biosciences? The SEC Central Index Key (CIK) for Jade Biosciences, Inc. is 1798749. Its filings are on SEC EDGAR. How many shares does Jade Biosciences have outstanding? 63,597,387 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is Jade Biosciences listed under? Our directory records Jade Biosciences, Inc. under United States. What does Jade Biosciences do? Our directory classifies Jade Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Jade Biosciences? The ISIN recorded for Jade Biosciences, Inc. is US0080642061. Does aibio.space cover Jade Biosciences? aibio.space lists Jade Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Jade Biosciences incorporated? SEC records list its state or country of incorporation as DE. What does Jade Biosciences develop? Jade Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapies for patients with autoimmune diseases. Its approach is to develop biologics against emerging targets supported by third-party clinical data and to overcome shortcomings of existing candidates in potency, bioavailability, formulation and pharmacokinetic properties. What is JADE101 from Jade Biosciences? JADE101: Half-life extended antibody targeting APRIL for IgA nephropathy Stage: Phase 1; Phase 2 planned. What is JADE201 from Jade Biosciences? JADE201: Half-life extended, afucosylated antibody targeting BAFF-R for autoimmune disorders Is Jade Biosciences profitable? Jade Biosciences, Inc. reported a net loss of $127.4 million for the fiscal year ended Dec 31, 2025, and used $94.7 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Jade Biosciences Members talk about Jade Biosciences (JBIO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Jade Biosciences, newest first. Each line links the filing it comes from. 1. 2026-06-03 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1798749/000119312526255444/d144482d424b5.htm) 2. 2026-05-07 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1798749/000119312526212422/d132368ds3.htm) 3. 2025-12-15 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1798749/000119312525318436/d90753dex991.htm) 4. 2025-11-14 Listings Reported a reverse stock split. SEC Form 8-K (Items 2.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1798749/000119312525281498/d26766dex991.htm) 5. 2025-11-14 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1798749/000119312525282921/d16462ds1.htm) 6. 2025-10-07 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1798749/000119312525232562/d58004dex991.htm) 7. 2025-08-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1798749/000119312525179853/ck0001798749-20250630.htm) 8. 2025-05-14 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1798749/000119312525119856/d72148dex991.htm) 9. 2025-05-01 Legal Reported a change of independent auditor. SEC Form 8-K (Items 1.01,2.01,2.02,3.03,4.01,5.01,5.02,5.03,5.05,5.06,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1798749/000119312525110004/d847557dex991.htm) 10. 2025-04-23 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1798749/000155837025005278/avte-20250423x8k.htm) 11. 2025-04-21 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1798749/000110465925036566/tm2512432d1_ex99-1.htm) 12. 2025-03-27 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1798749/000155837025003750/avte-20241231x10k.htm) 13. 2025-03-03 Mergers Reported a merger or acquisition agreement. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1798749/000110465925019830/tm254409d2_425.htm) 14. 2024-10-31 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,5.01,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1798749/000110465924112896/tm2427147d1_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:JBIO on TradingView](https://www.tradingview.com/symbols/NASDAQ-JBIO/). ## SEC filings and registration - **SEC name**: Jade Biosciences, Inc. - **CIK**: 1798749 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: JBIO (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 221 CRESCENT ST., WALTHAM, MA, 02453 - **Phone**: (781) 312-3013 - **Shares outstanding**: 63,597,387 as of 2026-08-03 (10-Q filed 2026-08-10) - **Former names**: Aerovate Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1798749/000119312526408287/d936098d8k.htm) filed 2026-09-30 - [10-Q](https://www.sec.gov/Archives/edgar/data/1798749/000119312526341242/ck0001798749-20260630.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/d40629d8k.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1798749/000119312526292704/d145208d8k.htm) filed 2026-07-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1798749/000119312526283906/d127137d8k.htm) filed 2026-06-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1798749/000119312526267640/d161530d8k.htm) filed 2026-06-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1798749/000119312526257733/d103726d8k.htm) filed 2026-06-04 - [424B5](https://www.sec.gov/Archives/edgar/data/1798749/000119312526257722/d144482d424b5.htm) filed 2026-06-04 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001798749), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Jade Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker JBIO, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Jade Biosciences, Inc. - **Ticker**: JBIO - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US0080642061 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-JBIO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/jade-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Jade Biosciences (JBIO) news: offering and merger", 2026-10-31, https://aibio.space/companies/jade-biosciences/